Nallamill Manoj Venkateswara Reddy and Mukthinuthalapati Mathrusri Annapurna*

Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM University, Visakhapatnam, India

*Corresponding Author: Mukthinuthalapati Mathrusri Annapurna, Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM University, Visakhapatnam, India.

Received: January 22, 2024; Published: January 27, 2024

Abstract

Efavirenz is a non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In the present study the authors have summarised the analytical techniques so far developed for the estimation of Efavirenz in pharmaceutical formulations as well as the biological fluids.

Keywords: Efavirenz; Spectrophotometry; HPLC; HPTLC; LC-MS/MS

References

1. Ruiz N. “Clinical history of Efavirenz”. International Journal of Clinical Practice 103 (1999): 3-7.
2. Muni Bhaskar Reddy CR and Venkata Subbareddy GG. “UV-spectrophotometric method for estimation of Efavirenz in bulk and tablet dosage form”. International Journal of Pharmacal Sciences and Research12 (2012): 5033-5037.
3. Srilatha P., et al. “Quantitative determination of Efavirenz in bulk drug and formulation by colorimetry”. Advances in Applied Science Research4 (2014): 176-180.
4. Narasimha Rao BV., et al. “Method development and validation of Efavirenz by UV spectrophotometer”. IOSR Journal of Pharmacy and Biological Sciences1 (2020): 15-18.
5. Deepan T., et al. “Spectroscopic determination of Efavirenz in bulk and pharmaceutical dosage form”. International Journal of Pharmacy and Medical Sciences1 (2015): 9-14.
6. Ajit KN., et al. “Development and validation of UV spectrophotometric methods for estimation of Efavirenz in bulk and tablet dosage form”. Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry3 (2014): 134-144.
7. Shweta Gupta., et al. “Development and validation of reversed phase HPLC gradient method for the estimation of Efavirenz in plasma”. PLoS ONE5 (2017): e0174777.
8. Oksana IS., et al. “Development and validation of HPLC/UV-procedure for Efavirenz quantitative determination”. Journal of Pharmaceutical Sciences and Research11 (2018): 2829-2835.
9. Paramita Saha and Murali Monohar Pandey. “Design of Experiment (DoE)-Approach based RP-HPLC analytical method development and validation for estimation of Efavirenz in bulk and formulations”. Journal of Chromatographic Science 1 (2022): 35-44.
10. Vishal CG and Sanjaykumar BB. “Quantification and validation of stability-indicating RP-HPLC method for Efavirenz in bulk and tablet dosage form using Quality by Design (QbD): A Shifting Paradigm”. Journal of Chromatographic Science 2 (2022): 143-156.
11. Sumanth KS., et al. “A new and precise bio-analytical method development and validation for the estimation of Efavirenz in human plasma by RP-HPLC”. International Journal of Pharmaceutical, Chemical and Biological Sciences3 (2019): 106-122.
12. Osnir de Sá Viana., et al. “Development and validation of a HPLC analytical assay method for Efavirenz tablets: a medicine for HIV infections”. Brazilian Journal of Pharmaceutical Sciences 1 (2011): 97-102.
13. Waghmare Santosh A and Kashid Arun M. “Reverse Phase-High Performance Liquid Chromatography method development and validation for estimation of Efavirenz by Quality by Design approach”. Journal of Drug Delivery and Therapeutics (1-s) (2019): 319-330.
14. Ravisankar P., et al. “Novel analytical method development and validation for the quantitative analysis of Efavirenz in bulk and pharmaceutical dosage forms by RP-HPLC”. The Pharma Innovation Journal9 (2014): 32-39.
15. Punam SD. “Development and validation of high-performance liquid chromatographic method for analysis of Efavirenz in capsule dosage form”. International Journal of Scientific Research in Science and Technology 5 (2019): 307-322.
16. Emile Bienvenua., et al. “A rapid and selective HPLC-UV method for the quantitation of efavirenz in plasma from patients on concurrent HIV/AIDS and tuberculosis treatments”. Biomedical Chromatography11 (2013): 1554-1559.
17. Purnima DH., et al. “Optimization and validation of RP-HPLC stability-indicating method for determination of Efavirenz and its degradation products”. International Journal of Applied Science and Engineering 2 (2010): 155-165.

Citation

Citation: Nallamill Manoj Venkateswara Reddy and Mukthinuthalapati Mathrusri Annapurna. “Analytical Methods for the Assay of Efavirenz - A Review".Acta Scientific Pharmaceutical Sciences 8.2 (2024): 61-63.

Copyright

Copyright: © 2024 Nallamill Manoj Venkateswara Reddy and Mukthinuthalapati Mathrusri Annapurna. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.